Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.

Leng X, Ding T, Lin H, Wang Y, Hu L, Hu J, Feig B, Zhang W, Pusztai L, Symmans WF, Wu Y, Arlinghaus RB.

Cancer Res. 2009 Nov 15;69(22):8579-84. doi: 10.1158/0008-5472.CAN-09-1934. Epub 2009 Nov 3.

2.

Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis.

Berger T, Cheung CC, Elia AJ, Mak TW.

Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):2995-3000. doi: 10.1073/pnas.1000101107. Epub 2010 Feb 1.

3.

Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression.

Drew BG, Hamidi H, Zhou Z, Villanueva CJ, Krum SA, Calkin AC, Parks BW, Ribas V, Kalajian NY, Phun J, Daraei P, Christofk HR, Hewitt SC, Korach KS, Tontonoz P, Lusis AJ, Slamon DJ, Hurvitz SA, Hevener AL.

J Biol Chem. 2015 Feb 27;290(9):5566-81. doi: 10.1074/jbc.M114.606459. Epub 2014 Dec 2.

4.

Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation.

Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D.

Cancer Res. 2009 Dec 15;69(24):9163-8. doi: 10.1158/0008-5472.CAN-09-2483.

5.

HGF mediated upregulation of lipocalin 2 regulates MMP9 through nuclear factor-κB activation.

Koh SA, Lee KH.

Oncol Rep. 2015 Oct;34(4):2179-87. doi: 10.3892/or.2015.4189. Epub 2015 Aug 10.

PMID:
26259977
6.

ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.

Mahadevan NR, Rodvold J, Almanza G, Pérez AF, Wheeler MC, Zanetti M.

BMC Cancer. 2011 Jun 7;11:229. doi: 10.1186/1471-2407-11-229.

7.

Lipocalin 2 promotes lung metastasis of murine breast cancer cells.

Shi H, Gu Y, Yang J, Xu L, Mi W, Yu W.

J Exp Clin Cancer Res. 2008 Dec 12;27:83. doi: 10.1186/1756-9966-27-83.

8.

Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.

Chung IH, Chen CY, Lin YH, Chi HC, Huang YH, Tai PJ, Liao CJ, Tsai CY, Lin SL, Wu MH, Chen CY, Lin KH.

Oncotarget. 2015 Jun 20;6(17):15050-64.

9.

Lipocalin 2 is a regulator of macrophage polarization and NF-κB/STAT3 pathway activation.

Guo H, Jin D, Chen X.

Mol Endocrinol. 2014 Oct;28(10):1616-28. doi: 10.1210/me.2014-1092. Epub 2014 Aug 15.

10.

Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway.

Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, Kim DG.

Hepatology. 2013 Oct;58(4):1349-61. doi: 10.1002/hep.26467. Epub 2013 Aug 7.

PMID:
23696034
11.

Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma.

Mongre RK, Sodhi SS, Sharma N, Ghosh M, Kim JH, Kim N, Park YH, Shin YG, Kim SJ, Jiao ZJ, Huynh do L, Jeong DK.

Int J Oncol. 2016 Jan;48(1):84-98. doi: 10.3892/ijo.2015.3245. Epub 2015 Nov 13.

12.

Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.

Gaudineau B, Fougère M, Guaddachi F, Lemoine F, de la Grange P, Jauliac S.

J Cell Sci. 2012 Oct 1;125(Pt 19):4475-86. doi: 10.1242/jcs.099879. Epub 2012 Jul 5.

13.

Lipocalin 2 promotes breast cancer progression.

Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, Strong RK, Zurakowski D, Moses MA.

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8. doi: 10.1073/pnas.0810617106. Epub 2009 Feb 23.

14.
15.

Lipocalin 2 promotes the migration and invasion of esophageal squamous cell carcinoma cells through a novel positive feedback loop.

Du ZP, Wu BL, Xie YM, Zhang YL, Liao LD, Zhou F, Xie JJ, Zeng FM, Xu XE, Fang WK, Li EM, Xu LY.

Biochim Biophys Acta. 2015 Oct;1853(10 Pt A):2240-50. doi: 10.1016/j.bbamcr.2015.07.007. Epub 2015 Jul 17.

16.

Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.

Ding G, Fang J, Tong S, Qu L, Jiang H, Ding Q, Liu J.

Prostate. 2015 Jun 15;75(9):957-68. doi: 10.1002/pros.22978. Epub 2015 Feb 25.

PMID:
25728945
17.

Lipocalin 2 is essential for chronic kidney disease progression in mice and humans.

Viau A, El Karoui K, Laouari D, Burtin M, Nguyen C, Mori K, Pillebout E, Berger T, Mak TW, Knebelmann B, Friedlander G, Barasch J, Terzi F.

J Clin Invest. 2010 Nov;120(11):4065-76. doi: 10.1172/JCI42004.

18.

No effect of NGAL/lipocalin-2 on aggressiveness of cancer in the MMTV-PyMT/FVB/N mouse model for breast cancer.

Cramer EP, Glenthøj A, Häger M, Juncker-Jensen A, Engelholm LH, Santoni-Rugiu E, Lund LR, Laerum OD, Cowland JB, Borregaard N.

PLoS One. 2012;7(6):e39646. doi: 10.1371/journal.pone.0039646. Epub 2012 Jun 21.

19.

Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis.

Borkham-Kamphorst E, van de Leur E, Zimmermann HW, Karlmark KR, Tihaa L, Haas U, Tacke F, Berger T, Mak TW, Weiskirchen R.

Biochim Biophys Acta. 2013 May;1832(5):660-73. doi: 10.1016/j.bbadis.2013.01.014. Epub 2013 Jan 31.

20.

Lipocalin2 enhances the matrix metalloproteinase-9 activity and invasion of extravillous trophoblasts under hypoxia.

Kobara H, Miyamoto T, Suzuki A, Asaka R, Yamada Y, Ishikawa K, Kikuchi N, Ohira S, Shiozawa T.

Placenta. 2013 Nov;34(11):1036-43. doi: 10.1016/j.placenta.2013.08.004. Epub 2013 Aug 20.

PMID:
23972287

Supplemental Content

Support Center